心血管

订阅

MedSci主页 / 所有栏目 / 心血管

ACC 2014：GAUSS-2研究：evolocumab或可用于他汀不耐受患者

2014-03-31 小田 译 医学论坛网

降脂他汀
关注

PCSK9单克隆抗体evolocumab在本次美国心脏病学会年会(ACC2014)上可谓是风头正猛，如29日报道的多中心RUTHERFORD-2研究、MENDEL-2研究和DESCARTES研究结果均为阳性。30日有关evolocumab的研究又闪亮登场，这项研究表明，在他汀类药物不耐受的高胆固醇血症高危人群的治疗方面，evolocumab是一种前景比较好的联合治疗方法。研究论文3月30日在线发表

PCSK9单克隆抗体evolocumab在本次美国心脏病学会年会(ACC2014)上可谓是风头正猛，如29日报道的多中心RUTHERFORD-2研究、MENDEL-2研究和DESCARTES研究结果均为阳性。30日有关evolocumab的研究又闪亮登场，这项研究表明，在他汀类药物不耐受的高胆固醇血症高危人群的治疗方面，evolocumab是一种前景比较好的联合治疗方法。研究论文3月30日在线发表于《美国心脏病学杂志》（J Am Coll Cardiol）。

GAUSS-2是一项为期12周的双盲试验，旨在评估他汀类药物不耐受患者应用PCSK9单克隆抗体的效果，研究者随机将患者以2:2:1:1的比例分为evolocumab 140 mg [2周一次(Q2W)]或evolocumab 420 mg[每月一次(QM)]，两组均同时给予安慰剂(PBO)口服; 或皮下注射PBO (Q2W或QM)，两组均给予依折麦布10 mg口服。主要终点为患者基线低密度脂蛋白胆固醇(LDL-C)至12周和平均10周、12周的变化。

结果显示，共307例患者(平均年龄为62岁，平均LDL-C为193 mg/dl)纳入随机化研究。Evolocumab对LDL-C水平的降幅为53-56%，相对依折麦布的治疗差异为37-39% (P < 0.001)。evolocumab治疗组和依折麦布治疗组患者肌肉不良事件发生率分别为12%和23%。各治疗组出现紧急治疗不良事件和实验室异常均相当。

evolocumab将会对其余两种降脂药(他汀类药物和依折麦布)有何影响?让我们拭目以待!


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947204, encodeId=de0f194e20471, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Thu Sep 25 23:57:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911642, encodeId=c485191164224, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 19 19:57:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324897, encodeId=8610132489e21, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426467, encodeId=387e142646e31, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=)]
    2014-09-25 ms8543593053280928

    #不耐受#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1947204, encodeId=de0f194e20471, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Thu Sep 25 23:57:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911642, encodeId=c485191164224, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 19 19:57:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324897, encodeId=8610132489e21, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426467, encodeId=387e142646e31, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=)]
    2014-09-19 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1947204, encodeId=de0f194e20471, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Thu Sep 25 23:57:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911642, encodeId=c485191164224, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 19 19:57:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324897, encodeId=8610132489e21, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426467, encodeId=387e142646e31, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=)]
    2014-04-02 12498568m50暂无昵称

    #ACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1947204, encodeId=de0f194e20471, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20463, encryptionId=78af204639e, topicName=不耐受)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Thu Sep 25 23:57:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911642, encodeId=c485191164224, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 19 19:57:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324897, encodeId=8610132489e21, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426467, encodeId=387e142646e31, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Wed Apr 02 02:57:00 CST 2014, time=2014-04-02, status=1, ipAttribution=)]
    2014-04-02 ZGMFX25A

    #Evolocumab#

    0

相关资讯

“降压10原则”与“他汀6原则”带给我们的思考

高血压与高血脂治疗主要以药物治疗为主，但怎样规范、有效进行药物治疗是我们长期思考及探索的一个课题。但降压药物和降脂药物的作用是有限的。不管是何种降压药物，每一种药物的降压效果只是10/5mmHg；每降低6％的LDL-C，就需要将他汀类药物的剂量加倍，这就是“降压药物10原则”及“他汀药物6原则”，那么，“降压10原则”及“他汀6原则”带给我们怎样的思考呢？ 1 “降压10原则”带来的思考 “血

PLoS One：降压/降脂复合制剂降低卒中和心脏病风险

   英国伦敦大学玛丽女王学院的研究人员在新一期PLoS One(《科学公共图书馆综合卷》）杂志上报告说，他们将氨氯地平、氯沙坦、氢氯噻嗪这三种降压药物和辛伐他汀这种降胆固醇药物混合在一起制成复合制剂，并以80多名50岁以上的中老年人为对象进行了随机对比试验。        结果显示，这种复合制剂可以使服药者血压平均降低12

IAS：non-HDL-C作为降脂治疗靶标更优

近期，国际动脉粥样硬化学会（IAS）公布全球血脂代谢异常处理指南。该指南以来源于多个领域的证据为依据，明确指出动脉粥样硬化性胆固醇既可指低密度脂蛋白胆固醇（LDL-C），也可指非高密度脂蛋白胆固醇（non-HDL-C），但更支持以后者作为降脂治疗靶标；强调动脉粥样硬化性心血管疾病（ASCVD）一级预防重在生活方式干预，而二级预防需依靠药物；血脂代谢异常患者的ASCVD风险评估应评估长期风险，而非短

赵水平：急性冠脉综合征如何调脂治疗？

中南大学湘雅二医院心血管内科  赵水平急 性冠状动脉综合征（ACS）患者特别是急性心肌梗死（AMI）患者，可因应激状态，基线血脂浓度有较大波动。AMI发生24h后，总胆固醇（TC）、低密 度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、载脂蛋白（apo）A1及apoB均有明显下降，而甘油三酯（TG）却增加；4～5d 后变化最为明显，2～3个月后可回到基线状态。此

李勇：降脂治疗新观念 聚焦总体风险评估与合理指标调控

复旦大学附属华山医院心脏科 李勇 动脉粥样硬化是多重危险因素共同作用的结果。因此，处理血脂异常预防动脉粥样硬化必须同时考虑不同危险因素合并存在的状态所导致心血管病危险的差异，即全身心血管风险评估。流行病学研究表明，总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）是最重要的心血管终点事件的血脂预测指标。一系列研究证实，他汀类药物不仅能显著降低TC和LDL-C，并能显著降低新发和再发心血管终点事件

降脂：不能服用他汀的患者LDL如何达标？

降脂达标已成为防治动脉粥样硬化性心血管疾病的核心策略，而他汀类药物被视为血脂异常和抗动脉粥样硬化药物治疗的基石。然而，中国第二次血脂治疗现状调查结果显示，采用他汀稳定剂量治疗的高胆固醇血症患者胆固醇水平达标率低，尤为严重的是高危、极高危患者的达标率仅为39%和23%.究其原因，许多患者在接受较大剂量他汀治疗后其胆固醇水平仍不能达到目标值以下，另有一些患者由于种种原因（肝功能